drug development
drug development at Beyond Market Intelligence is a file of 3 stories. The newest of them: “Proximal Ventures Invests $27.5 Million in AI for Drug Development”, “AI Biotech Enveda Accelerates Drug Development with $311M Investment”, and “Why open data, not moats, will let AI engineer better medicine”. Sahir Raoof just raised $27.5 million for Proximal Ventures, a new fund targeting AI-driven drug development. Enveda's $311M raise isn't just a big number; it's a signal that AI-driven drug discovery is moving from promise to pipeline. Acme AI is the next-generation, AI-powered spreadsheet platform built to replace Excel and redefine how analysts, data scientists, and enterprise teams work… The list below is every drug development story on Beyond Market Intelligence, newest first.
Proximal Ventures Invests $27.5 Million in AI for Drug Development
Sahir Raoof just raised $27.5 million for Proximal Ventures, a new fund targeting AI-driven drug development. That capital signals serious confidence in applying modern AI to the slow, expensive work of discovering new therapies. Legacy approaches to pharmaceutical R&D are overdue for an upgrade. For readers who want to see how AI can simplify complex data, our piece on Usul's approach to neural networks offers a practical look under the hood.
AI Biotech Enveda Accelerates Drug Development with $311M Investment
Enveda's $311M raise isn't just a big number; it's a signal that AI-driven drug discovery is moving from promise to pipeline. The $2B valuation reflects real momentum, especially as the company targets skin conditions and tackles the stubborn problem of weight regain after GLP-1s. That's practical science with tangible outcomes. We're watching a biotech that understands the patient's journey, not just the lab bench. For more on who's betting big on emerging tech, check our piece on Wahlberg and Lee's upcoming Disrupt discussion.
Why open data, not moats, will let AI engineer better medicine
Vijay Pande walked away from managing $4 billion at a16z to bet smaller, and that restraint is exactly the point. His new firm, VZVC, leans into AI-native investing because he sees biology shifting from discovery to engineering. Clinical trials remain brutally expensive, and he argues open, shared datasets will matter more than proprietary walls. That conviction feels right. For a deeper look at how AI handles messy real-world data, our piece on real-world computer vision deployments is worth reading.